DAIICHI SANKYO CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,502 JPY | +3.13% |
|
+17.99% | +42.10% |
| Apr. 30 | Remsons, Daiichi Infotainments Form Joint Venture | MT |
| Apr. 29 | AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement | MT |
| Sales 2024 | 1,602B 10.31B | Sales 2025 * | 1,761B 11.33B | Capitalization | 10,230B 65.83B |
|---|---|---|---|---|---|
| Net income 2024 | 201B 1.29B | Net income 2025 * | 187B 1.2B | EV / Sales 2024 | 5.72 x |
| Net cash position 2024 * | 556B 3.58B | Net cash position 2025 * | 647B 4.16B | EV / Sales 2025 * | 5.44 x |
| P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
51.7
x | Employees | 17,435 |
| Yield 2024 |
1.05% | Yield 2025 * |
1.07% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Co., Ltd.
More recommendations
More press releases
More news
| 1 day | +3.13% | ||
| 1 week | +17.99% | ||
| Current month | +15.18% | ||
| 1 month | +17.89% | ||
| 3 months | +26.40% | ||
| 6 months | +41.99% | ||
| Current year | +42.10% |
1 week
4 612.00
5 520.00
1 month
4 443.005 520.00
Current year
3 847.005 520.00
1 year
3 566.005 520.00
3 years
1 981.005 520.00
5 years
1 731.005 520.00
10 years
518.675 520.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.16% | 15 M€ | +11.75% | ||
| 4.18% | 251 M€ | +13.17% | ||
| 3.32% | 174 M€ | -.--% | - | |
| 3.32% | 51 M€ | -.--% | - | |
| 3.24% | 15 M€ | +16.04% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 5,502 | +3.13% | 5 318 200 |
| 24-05-01 | 5,335 | -0.54% | 5,583,300 |
| 24-04-30 | 5,364 | +7.07% | 10,768,000 |
| 24-04-26 | 5,010 | +5.12% | 9,590,300 |
| 24-04-25 | 4,766 | +0.78% | 8,225,700 |
Delayed Quote Japan Exchange, May 02, 2024 at 02:00 am EDT
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,335
JPY
Average target price
5,673
JPY
Spread / Average Target
+6.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +42.10% | 64.91B | |
| +33.25% | 699B | |
| +25.27% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +15.09% | 236B | |
| +5.16% | 198B | |
| -9.98% | 194B | |
| -3.69% | 149B |
- Stock Market
- Equities
- 4568 Stock
